Provisions of the Affordable Care Act

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Research, SG, News, GAAP, Carcinoma, R, Orphan, Clinical trial, CARES Act, Total, Provisions of the Affordable Care Act, Fine chemical, Video game, Pharmaceutical industry, Pfizer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023.
  • Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022.
  • Product revenue, net in the third quarter of 2023 was $51.6 million, compared to $54.3 million in the third quarter of 2022.
  • Total other expenses were $2.6 million for the third quarter of 2023, compared to $2.7 million for the third quarter of 2022.

More than a Quarter (28%) of Americans with Health Insurance Can't Afford Their Deductibles

Retrieved on: 
Wednesday, November 1, 2023
Public, Affordable Care Act, Insurance, Fintech, COVID-19, Risk, Provisions of the Affordable Care Act, YouGov, Health insurance, Medicaid

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- The Affordable Care Act was introduced more than a decade ago, making several preventative services available at no charge to millions of Americans. But many are still struggling to financially cover their basic health care needs.

Key Points: 
  • Even 18% of Americans with health insurance and earning $80,000 or more a year said they would have to borrow money or use mostly credit to cover their deductibles, making them "underinsured."
  • A staggering 45% of insured Americans have even avoided medical care because they knew or feared their health insurance wouldn't cover the costs.
  • The Policygenius 2023 Health Insurance Survey also found that:
    Among insured Americans who have seen a mental health provider, 42% have had their health insurance declined.
  • 9% of insured Americans said they would go without insurance coverage if they lost their current health insurance, while 25% aren't sure what they would do.

SureCo Analysis Finds ICHRAs Vastly Expand Consumer Choice, Strengthen Individual Insurance Markets

Retrieved on: 
Monday, October 30, 2023
Lundström, Insurance, ACA, Ageing, Care Act 2014, Gold, Kaiser Family Foundation, Acqui-hiring, Provisions of the Affordable Care Act, Health insurance, Management

SANTA ANA, Calif., Oct. 30, 2023 /PRNewswire/ -- While most employers offer only one health plan to their employees, employees with employer-sponsored Individual Coverage Health Reimbursement Arrangements (ICHRAs) on average are choosing from 23 plans, according to a new survey by SureCo, the leader in helping businesses provide customized healthcare options to employees.

Key Points: 
  • A sample analysis of over 4,000 employees in ICHRA plans also found the average age of people enrolled is 34 years old.
  • This variety of choices ICHRAs offer is in sharp contrast to limited offerings employers provide through group health insurance plans.
  • "With employees at different life stages and spread across various locations, traditional group benefits struggle to accommodate everyone's individual needs.
  • It also contradicts the naysayers who predicted ICHRAs would weaken individual markets by overburdening them with older employees with more health problems.

Sendero Health Plans Names Sharon Alvis as Next Chief Executive

Retrieved on: 
Thursday, September 21, 2023
Insurance, EAP, Health, Central Health, Saint David, PHO, PPO, Central Health (Texas), HMO, Preferred provider organization, Health maintenance organization, Organization, Medicare, Hospital, Affordable Care Act, Hugh Delargy, ACA, Physician, National Hospital Organization Nagara Medical Center, Provisions of the Affordable Care Act, Alvis, St Davids, Health insurance marketplace, Curative, Health insurance, Retail, Central Texas

AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Sendero Health Plans Inc. (Sendero) announced Wednesday it has named Sharon J. Alvis as the new chief executive officer to lead the nonprofit health maintenance organization (HMO), which was created and is funded and owned by Central Health.
  • Sendero offers health insurance plans through the Affordable Care Act's (ACA) federal Health Insurance Marketplace.
  • I have closely followed the evolution and experience of Sendero Health Plans from its inception and was excited about the potential to directly contribute."
  • Alvis continued, "With its unique structure and ownership, Sendero, in collaboration with the Central Health System, has a unique opportunity to maximize powerful collective resources.

Financial Literacy Group Releases A Study That Shows An IUL is Superior as a Retirement Instrument When Compared to a 401K or IRA, After the Cares Act 2020

Retrieved on: 
Tuesday, September 19, 2023
IRAS, Tradition, Main Street, Insurance, Tax, Small business, ETF, IRS, Policy, COVID-19, Indexed universal life, App Store (iOS/iPadOS), IUL, Income tax, Mid-range, Wall Street, IRA, CARES Act, Index, Reuters, Retirement, Roth, Investment, Risk, Provisions of the Affordable Care Act, Google Play, Growth, Bank, Longevity, Bias, Family, Financial adviser, Life insurance, Pension fund

SANTA MONICA, Calif., Sept. 19, 2023 /PRNewswire-PRWeb/ -- The CARES Act, passed in 2020, brought several changes to the IRS codes 7702 and 101(a), which impacted the Index Universal Life (IUL) insurance policies, along with other life insurance policies.

Key Points: 
  • Financial Literacy Group Releases a white paper study that shows an Index Universal Insurance policy is superior as a retirement instrument when compared to a 401K or IRA, especially after the CARES Act 2020.
  • Index Universal Life (IUL) Insurance is a type of permanent life insurance policy that has a cash value component, which can be invested in index-linked options.
  • IUL policies provide a death benefit and also have a cash value component that grows on a tax deferred basis.
  • Financial Literacy Group is changing the narrative on financial wellness, our solutions equalize the financial playing field between middle class Americans and financial institutions.

NAPEO Calls IRS Decision to Focus on Existing ERTC Claims a "Step in the Right Direction"

Retrieved on: 
Friday, September 15, 2023
Small business, IRS, Provisions of the Affordable Care Act, Internal Revenue Service, COVID-19, Professional employer organization, Congress, United States House Ways and Means Subcommittee on Social Security, Radio, National Association, Ways and means committee, Television, Cryptocurrency

ALEXANDRIA, Va., Sept. 15, 2023 /PRNewswire/ -- The Internal Revenue Service's (IRS) decision to pause new Employee Retention Credit (ERTC) claims should allow the agency to focus on processing legitimate claims and finally clear the backlog that has left tens of thousands of small businesses waiting years for funds, the National Association of Professional Employer Organizations (NAPEO) said Friday. 

Key Points: 
  • "Over the past year, we've stood shoulder-to-shoulder with the IRS, warning our members and their small business clients of the perils of ERTC mills.
  • "We hope the IRS can expeditiously clear the backlog of legitimate ERTC claims, so that the thousands of small businesses still waiting can get the money they are entitled to."
  • The IRS on September 14 announced that it would pause the processing of new ERTC claims through at least the end of this year to focus on fraudulent claims that have exacerbated in recent months.
  • NAPEO supports the IRS's decision to quell these bad actors so it can focus on legitimate claims as quickly as possible.

United States Generic Drugs Market Trends and Forecast Report 2023-2028: Demand for Affordable High-Quality Drugs & Increasing Availability Fueling the Multi-Billion Industry - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 12, 2023
Manufacturing, Pharmaceutical, Oncology, Mental Health, Practice Management, Public Policy, Government, Managed Care, Cardiology, FDA, General Health, Biotechnology, Diabetes, Alternative Medicine, AIDS, Health, Healthcare Reform, Packaging, Health Insurance, Chemicals, Plastics, Online, Incidence, Teva Pharmaceuticals, Allergy, Asthma, Prevalence, Classification, Pharmacy, Policy, Cardiovascular disease, Prescription, Generic drug, Research, Counterfeit, Provisions of the Affordable Care Act, Compound annual growth rate, Parkinson's disease, Patient, Patent, Sun Pharma, Aurobindo Pharma, Cancer, Insight, Care Act 2014, Mental health, Safety, Alzheimer's disease, Legislation, Pharmaceutical industry, Grocery store, Growth

The "United States Generic Drugs Market, Forecast 2023-2028, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Generic Drugs Market, Forecast 2023-2028, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The United States Generic Drugs Market is on a robust trajectory, with a projected valuation of approximately $147.57 billion by 2028, surging from $101.77 billion in 2022.
  • California, Texas, New York, Florida, Pennsylvania, Ohio, Illinois, North Carolina, Georgia, Michigan, and other states play an instrumental role in the United States Generic Drugs Industry.
  • Increasing Availability: The ever-increasing number of generic drugs available in the market has led to a growth in commercial payments for these drugs.

Universal Technical Institute Reports Fiscal Year 2023 Third Quarter Results

Retrieved on: 
Tuesday, August 8, 2023
Advertising, Unemployment, Failure, Provisions of the Affordable Care Act, Regulation Fair Disclosure, Table, UTI, Universal Technical Institute, Bank statement, COVID-19, Disclosure, GAAP, Strategic planning, Credit agreements in South Africa, Forecasting, Public expenditure, EBITDA, Acquisition, Concorde, CARES Act, Depreciation, Security (finance), National Association, Credit, Regulation, Social media, Fifth Third Bank, Bank, Online shopping, Bookkeeping

PHOENIX, Aug. 8, 2023 /PRNewswire/ -- Universal Technical Institute, Inc. (NYSE: UTI), a leading workforce solutions provider of transportation, skilled trades and healthcare education programs, reported financial results for the fiscal 2023 third quarter ended June 30, 2023. Universal Technical Institute, Inc. operates in two reportable segments, Universal Technical Institute (UTI) and Concorde Career Colleges (Concorde), and together with its segments and subsidiaries is referred to as the "Company," "we," "us" or "our."

Key Points: 
  • Fiscal 2023 reflects UTI estimated results for the full year and Concorde estimated results beginning December 1, 2022.
  • Management will hold a conference call to discuss the financial results for the fiscal 2023 third quarter ended June 30, 2023, on Tuesday, August 8, 2023, at 4:30 p.m.
  • A live webcast of the call will be available via the Universal Technical Institute, Inc. investor relations website at https://investor.uti.edu .
  • Please go to the website at least 10 minutes early to register, download and install any necessary audio software.

Puma Biotechnology Reports Second Quarter Financial Results

Retrieved on: 
Thursday, August 3, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, Carcinoma, Provisions of the Affordable Care Act, SG, Clinical trial, Paclitaxel, GAAP, ASCO, Patient, CARES Act, R, Research, FDA, News, Society, Total, Video game, Pharmaceutical industry, Pfizer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023.
  • Unless otherwise stated, all comparisons are for the second quarter of 2023 compared to the second quarter of 2022.
  • Product revenue, net in the second quarter of 2023 was $51.6 million, an increase from $51.3 million reported for the second quarter of 2022.
  • Total other expenses were $2.6 million for the second quarter of 2023, essentially unchanged from the second quarter of 2022.

Pediatrix Medical Group Reports Second Quarter Results

Retrieved on: 
Thursday, August 3, 2023
Health, Consumer, Hospitals, Women, Other Health, Baby, Maternity, General Health, Borrowing base, Provisions of the Affordable Care Act, Pediatrix Medical Group, Continuous operation, Debt-to-GDP ratio, Tax, GAAP, Public expenditure, ET, EBITDA, Depreciation, Webcast, EPS, Adjustment, Pharmaceutical industry, Video game, Security (finance), Cryptocurrency, Bookkeeping

Depreciation and amortization expense was $8.9 million for the second quarter of 2023, compared to $8.8 million for the second quarter of 2022.

Key Points: 
  • Depreciation and amortization expense was $8.9 million for the second quarter of 2023, compared to $8.8 million for the second quarter of 2022.
  • Interest expense was $11.2 million for the second quarter of 2023, compared to $8.4 million for the second quarter of 2022.
  • For the second quarter of 2023, Pediatrix reported Adjusted EPS from continuing operations of $0.39, compared to $0.47 for the second quarter of 2022.
  • For the second quarter of 2023, Pediatrix generated cash from continuing operations of $92.6 million, compared to $81.6 million during the second quarter of 2022.